RxDoctor Payments Data

Thomas Weiss

Psychiatry · San Antonio, TXNPI 1063414928

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $596,336 of the $744,180 with a category attached, or 80.1%. AbbVie accounts for 78.1% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $190,964 and has fallen 68.5% since, to $60,159 in 2025. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$744,180in general payments, 2019–2025

Across 1,230 payments — averaging $605.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$581K
  • Axsome Therapeutics, Inc.$98K
  • Takeda Pharmaceuticals U.S.A., Inc.$24K
  • Eisai Inc.$19K
  • Vanda Pharmaceuticals Inc.$11K
  • Idorsia Pharmaceuticals US Inc$10K
  • plus $1K from 7 others
$336,625in research payments, 2019–2025

Across 132 payments — averaging $2550.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$238K
  • Acadia Pharmaceuticals Inc$74K
  • Takeda Pharmaceuticals U.S.A., Inc.$15K
  • Biohaven Pharmaceutical Holding Company Ltd.$9K

What the payments were for

  • Consulting fees$57,2508%
  • Speaking & faculty fees$596,33680%
  • Travel & lodging$75,76310%
  • Food & beverage$14,7512%
  • Education$780%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$744,180 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
Memantine Hcl15$526
Escitalopram Oxalate35$357
Duloxetine Hcl14$308
Clonazepam12$288
Bupropion XlBupropion Hcl19$273
Olanzapine11$116
Quetiapine Fumarate14$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$86$11611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →